547 related articles for article (PubMed ID: 24161319)
1. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
Roncarati R; Viviani Anselmi C; Losi MA; Papa L; Cavarretta E; Da Costa Martins P; Contaldi C; Saccani Jotti G; Franzone A; Galastri L; Latronico MV; Imbriaco M; Esposito G; De Windt L; Betocchi S; Condorelli G
J Am Coll Cardiol; 2014 Mar; 63(9):920-7. PubMed ID: 24161319
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy.
Fang L; Ellims AH; Moore XL; White DA; Taylor AJ; Chin-Dusting J; Dart AM
J Transl Med; 2015 Sep; 13():314. PubMed ID: 26404540
[TBL] [Abstract][Full Text] [Related]
3. Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters.
Sonsöz MR; Yilmaz M; Cevik E; Orta H; Bilge AK; Elitok A; Onur I; Komurcu-Bayrak E
Heart Lung Circ; 2022 Feb; 31(2):199-206. PubMed ID: 34088630
[TBL] [Abstract][Full Text] [Related]
4. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM.
Li M; Chen X; Chen L; Chen K; Zhou J; Song J
J Transl Med; 2018 Jun; 16(1):161. PubMed ID: 29885652
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of microRNAs in patients with hypertrophic cardiomyopathy.
Scolari FL; Faganello LS; Garbin HI; Piva E Mattos B; Biolo A
Int J Cardiol; 2021 Mar; 327():146-154. PubMed ID: 33212095
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art.
Angelopoulos A; Oikonomou E; Vogiatzi G; Antonopoulos A; Tsalamandris S; Georgakopoulos C; Papanikolaou P; Lazaros G; Charalambous G; Siasos G; Vlachopoulos C; Tousoulis D
Curr Med Chem; 2021; 28(36):7400-7412. PubMed ID: 33820510
[TBL] [Abstract][Full Text] [Related]
7. A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy.
Thottakara T; Lund N; Krämer E; Kirchhof P; Carrier L; Patten M
Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827715
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy.
Huang D; Chen Z; Wang J; Chen Y; Liu D; Lin K
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31868204
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma levels of miR-29a are associated with hemolysis in patients with hypertrophic cardiomyopathy.
Ntelios D; Meditskou S; Efthimiadis G; Pitsis A; Nikolakaki E; Girtovitis F; Parcharidou D; Zegkos T; Kouidou S; Karvounis H; Tzimagiorgis G
Clin Chim Acta; 2017 Aug; 471():321-326. PubMed ID: 28684219
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker.
Dai Y; Dai D; Mehta JL
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2181. PubMed ID: 25457411
[No Abstract] [Full Text] [Related]
11. Reply: MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker.
Condorelli G
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2181-2. PubMed ID: 25457410
[No Abstract] [Full Text] [Related]
12. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy.
Derda AA; Thum S; Lorenzen JM; Bavendiek U; Heineke J; Keyser B; Stuhrmann M; Givens RC; Kennel PJ; Schulze PC; Widder JD; Bauersachs J; Thum T
Int J Cardiol; 2015 Oct; 196():115-22. PubMed ID: 26086795
[TBL] [Abstract][Full Text] [Related]
13. [The levels of certain circulating microRNAs in hypertrophic cardiomyopathy are associated with echocardiographic parameters].
Pisklova MV; Baulina NM; Kiselev IS; Zateyshchikov DA; Favorova OO; Chumakova OS
Ter Arkh; 2023 May; 95(4):302-308. PubMed ID: 38158977
[TBL] [Abstract][Full Text] [Related]
14. Circulating miRNAs as Potential Biomarkers Associated with Cardiac Remodeling and Fibrosis in Chagas Disease Cardiomyopathy.
Nonaka CKV; Macêdo CT; Cavalcante BRR; Alcântara AC; Silva DN; Bezerra MDR; Caria ACI; Tavora FRF; Neto JDS; Noya-Rabelo MM; Rogatto SR; Ribeiro Dos Santos R; Souza BSF; Soares MBP
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434314
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of miR-199a-3p in a murine hypertrophic cardiomyopathy (HCM) model attenuates fibrotic remodeling.
Zalivina I; Barwari T; Yin X; Langley SR; Barallobre-Barreiro J; Wakimoto H; Zampetaki A; Mayr M; Avkiran M; Eminaga S
J Mol Cell Cardiol Plus; 2023 Dec; 6():100056. PubMed ID: 38143961
[TBL] [Abstract][Full Text] [Related]
16. MiRNA-Regulated Pathways for Hypertrophic Cardiomyopathy: Network-Based Approach to Insight into Pathogenesis.
Osmak G; Baulina N; Kiselev I; Favorova O
Genes (Basel); 2021 Dec; 12(12):. PubMed ID: 34946964
[TBL] [Abstract][Full Text] [Related]
17. LncRNA-MIAT regulates fibrosis in hypertrophic cardiomyopathy (HCM) by mediating the expression of miR-29a-3p.
Zhou J; Zhou Y; Wang CX
J Cell Biochem; 2019 May; 120(5):7265-7275. PubMed ID: 30548303
[TBL] [Abstract][Full Text] [Related]
18. Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.
Hiremath P; Lawler PR; Ho JE; Correia AW; Abbasi SA; Kwong RY; Jerosch-Herold M; Ho CY; Cheng S
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623770
[TBL] [Abstract][Full Text] [Related]
19. Differential Expression of microRNAs in Hypertrophied Myocardium and Their Relationship to Late Gadolinium Enhancement, Left Ventricular Hypertrophy and Remodeling in Hypertrophic Cardiomyopathy.
Zhang C; Zhang H; Zhao L; Wei Z; Lai Y; Ma X
Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010328
[No Abstract] [Full Text] [Related]
20. Circulating miRNA29 family expression levels in patients with essential hypertension as potential markers for left ventricular hypertrophy.
Huang Y; Tang S; Huang C; Chen J; Li J; Cai A; Feng Y
Clin Exp Hypertens; 2017; 39(2):119-125. PubMed ID: 28287884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
